Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern
David W. Hawman, Kimberly Meade‐White, Jacob Archer, et al.
eLife (2022) Vol. 11
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Nanoparticles in Clinical Trials: Analysis of Clinical Trials, FDA Approvals and Use for COVID-19 Vaccines
Eugenia D. Namiot, Aleksandr V. Sokolov, Vladimir N. Chubarev, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 1, pp. 787-787
Open Access | Times Cited: 76
SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic
Chiranjib Chakraborty, Manojit Bhattacharya, Kuldeep Dhama
Vaccines (2023) Vol. 11, Iss. 3, pp. 682-682
Open Access | Times Cited: 59
Cross-protection induced by highly conserved human B, CD4+, and CD8+ T-cell epitopes-based vaccine against severe infection, disease, and death caused by multiple SARS-CoV-2 variants of concern
Swayam Prakash, Nisha R. Dhanushkodi, Latifa Zayou, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 15
Replicating RNA vaccination elicits an unexpected immune response that efficiently protects mice against lethal Crimean-Congo hemorrhagic fever virus challenge
Shanna Leventhal, Kimberly Meade‐White, Deepashri Rao, et al.
EBioMedicine (2022) Vol. 82, pp. 104188-104188
Open Access | Times Cited: 45
Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine
David W. Hawman, Kimberly Meade‐White, Chad S. Clancy, et al.
EBioMedicine (2022) Vol. 83, pp. 104196-104196
Open Access | Times Cited: 41
Fc-mediated pan-sarbecovirus protection after alphavirus vector vaccination
Lily E. Adams, Sarah R. Leist, Kenneth H. Dinnon, et al.
Cell Reports (2023) Vol. 42, Iss. 4, pp. 112326-112326
Open Access | Times Cited: 35
Pre-existing immunity modulates responses to mRNA boosters
Tanushree Dangi, Sarah Sanchez, Min Han Lew, et al.
Cell Reports (2023) Vol. 42, Iss. 3, pp. 112167-112167
Open Access | Times Cited: 34
Rise of the RNA machines – self-amplification in mRNA vaccine design
Jerôme D.G. Comes, Gorben P. Pijlman, Tessy A. H. Hick
Trends in biotechnology (2023) Vol. 41, Iss. 11, pp. 1417-1429
Open Access | Times Cited: 33
A localizing nanocarrier formulation enables multi-target immune responses to multivalent replicating RNA with limited systemic inflammation
Taishi Kimura, Joseph M. Leal, Adrian Simpson, et al.
Molecular Therapy (2023) Vol. 31, Iss. 8, pp. 2360-2375
Open Access | Times Cited: 27
Self-Amplifying RNA: A Second Revolution of mRNA Vaccines against COVID-19
Noelia Silva-Pilipich, Uxue Beloki, Laura Salaberry, et al.
Vaccines (2024) Vol. 12, Iss. 3, pp. 318-318
Open Access | Times Cited: 7
Design Strategies for and Stability of mRNA–Lipid Nanoparticle COVID-19 Vaccines
Ting Liu, Yang Tian, Aiping Zheng, et al.
Polymers (2022) Vol. 14, Iss. 19, pp. 4195-4195
Open Access | Times Cited: 32
The effect of COVID-19 vaccine to the Omicron variant in children and adolescents: a systematic review and meta-analysis
Wenting Lu, Shuai Zeng, Yuan Yao, et al.
Frontiers in Public Health (2024) Vol. 12
Open Access | Times Cited: 6
A self-amplifying RNA vaccine prevents enterovirus D68 infection and disease in preclinical models
Nikole L. Warner, Jacob Archer, Stephanie Park, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 759
Closed Access | Times Cited: 6
The Rise and Fall of SARS-CoV-2 Variants and Ongoing Diversification of Omicron
Tanner Wiegand, Artem Nemudryi, Anna Nemudraia, et al.
Viruses (2022) Vol. 14, Iss. 9, pp. 2009-2009
Open Access | Times Cited: 25
Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis?
Sasha E. Larsen, Susan L. Baldwin, Rhea N. Coler
International Journal of Infectious Diseases (2023) Vol. 130, pp. S47-S51
Open Access | Times Cited: 14
A replicon RNA vaccine can induce durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have waned
Megan A. O’Connor, David W. Hawman, Kimberly Meade‐White, et al.
PLoS Pathogens (2023) Vol. 19, Iss. 4, pp. e1011298-e1011298
Open Access | Times Cited: 12
Evaluation of repRNA vaccine for induction and in utero transfer of maternal antibodies in a pregnant rabbit model
Amit P. Khandhar, Chelsea D. Landon, Jacob Archer, et al.
Molecular Therapy (2023) Vol. 31, Iss. 4, pp. 1046-1058
Open Access | Times Cited: 9
Pre-existing immunity modulates responses to mRNA boosters
Tanushree Dangi, Sarah Sanchez, Min Han Lew, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 9
Leishmaniasis Vaccines: Applications of RNA Technology and Targeted Clinical Trial Designs
Malcolm S. Duthie, Bruna Aparecida Souza Machado, Roberto Badaró, et al.
Pathogens (2022) Vol. 11, Iss. 11, pp. 1259-1259
Open Access | Times Cited: 9
A gH/gL-encoding replicon vaccine elicits neutralizing antibodies that protect humanized mice against EBV challenge
Kristina R. Edwards, Harman Malhi, Karina Schmidt, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 1
Cross-Protection Induced by Highly Conserved Human B, CD4+,and CD8+T Cell Epitopes-Based Coronavirus Vaccine Against Severe Infection, Disease, and Death Caused by Multiple SARS-CoV-2 Variants of Concern
Swayam Prakash, Nisha R. Dhanushkodi, Latifa Zayou, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 4
Live-attenuated pediatric parainfluenza vaccine expressing 6P-stabilized SARS-CoV-2 spike protein is protective against SARS-CoV-2 variants in hamsters
Xueqiao Liu, Hong-Su Park, Yumiko Matsuoka, et al.
PLoS Pathogens (2023) Vol. 19, Iss. 6, pp. e1011057-e1011057
Open Access | Times Cited: 4
Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates
Patricia Pérez, Guillermo Albericio, David Astorgano, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 4
Vaccine Platform Comparison: Protective Efficacy against Lethal Marburg Virus Challenge in the Hamster Model
Kyle L. O’Donnell, Corey W. Henderson, Hanna Anhalt, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8516-8516
Open Access | Times Cited: 1
Fc mediated pan-sarbecovirus protection after alphavirus vector vaccination
Lily E. Adams, Sarah R. Leist, Kenneth H. Dinnon, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top